Implemented 18 clinical trial research projects to demonstrate the initial safety and efficacy of cell therapy in treating incurable diseases. Initial results are very promising:

Completed Phase 2 study using bone marrow-derived mononuclear cells for treating autism in children. The quality of life for autistic children improved positively post-transplant.  

Successfully concluded governmental-level research projects using bone marrow-derived mononuclear cells for treating cerebral palsy, with over 90% of transplanted patients showing improved motor function.

Completed Phase 1 studies demonstrating the safety of mesenchymal stem cells in treating diseases such as type 1 diabetes, hormone deficiency in men/women, stroke, traumatic brain injury, chronic obstructive pulmonary disease (COPD), pulmonary dysplasia, and anti-aging/rejuvenation in treating health decline in the elderly. Phase 2 trials are ongoing to evaluate the effectiveness of the therapy.

Implemented a key project utilizing CAR-T therapy in the treatment of hematological cancers. Initial results show complete remission in 87% of patients following CAR-T cell infusion. This represents the most advanced therapy proven effective in treating acute leukemia and lymphoma, offering new hope for patients unresponsive to conventional treatment protocols.  

Performed hematopoietic stem cell transplantation for patients with hematological cancers, thalassemia, primary immunodeficiency, etc., achieving a high success rate.

Developing gene therapy using CRISPR/Cas9 technology in Thalassemia treatment, marking itself the first gene editing project on stem cells in Vietnam. Successfully implementing the project will build Vinmec Research Institute of Stem Cell and Gene Technology as one of the few centers worldwide capable of applying this complex technology in human disease treatment.